Skip to main content
Selina M. Luger on Muck Rack

Selina M. Luger

As seen in: Nature, Wiley Online Library, JAMA Oncology, Science Magazine, Blood, OncLive, Value in Health Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Selina M.

Contact Selina M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SA15 A MULTI-COUNTRY RETROSPECTIVE CHART REVIEW OF TREATMENT PATTERNS AND RESOURCE USE IN PATIENTS WITH NEWLY DIAGNOSED PH-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING FIRST-LINE CONSOLIDATION THERAPY

|
By HongBo Yang, Jingyi Liu, Zoey Kang, Faraz Zaman, Selina M. Luger, Anna S. Gautam, Mandy Du, Xinglei Chai, Diana Boyko
| Value in Health Journal Verified
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Open in Who Shared View Duplicates (171) Issue with article?

Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia

|
By Zhenbo Tu, Jaewoong Lee, John Foley Verified, Ruifeng Sun, Kohei Kume, Mark Robinson, Kadriye Nehir Cosgun, Ning Ma, Christian Hurtz, Huimin Geng, Selina M. Luger, Mark Litzow, Elisabeth Paietta, Jianjun Chen, Nagarajan Vaidehi, Markus Müschen, Zhangliang Cheng
| Science Magazine Verified
Editor’s summary Although CD25 is a subunit of the IL-2 receptor on T cells, CD25-expressing cells in the leukemias B-ALL and AML do not respond to IL-2 and are associated with poor clinical outcome. Through experiments with mice and patient-derived xenografts, Lee et al. showed that loss of CD25 in acute leukemia resulted in hyperactive oncogenic tyrosine kinase signaling that reduced cell fitness and leukemic potential.
Open in Who Shared Issue with article?

The evolving therapeutic revolution in adult acute lymphoblastic leukemia

|
By Hagop Kantarjian, NITIN JAIN, Mark Litzow, Selina M. Luger
| Wiley Online Library Verified
CONFLICT OF INTEREST STATEMENT Hagop Kantarjian reports research grants and honoraria from AbbVie, Amgen, Ascentage, Bristol Myers Squibb Company, Daiichi-Sankyo, Immunogen, Jazz, Novartis, Pfizer, and Sanofi; and honoraria from Actinium (advisory board), Adaptive Biotechnologies, Aptitude Health, BioAscend, Delta Fly, Janssen Global, Oxford Biomedical, and Takeda oncology outside the submitted work.
Open in Who Shared Issue with article?
See all 10 licensed articles (14 Total)